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A Case of Isolated Light Chain Deposition Disease in the 
Duodenum
Light chain deposition disease (LCDD) is a rare disorder associated with a clonal proliferation 
of plasma cells, which synthesize abnormal monoclonal immunoglobulin light chains. 
LCDD is characterized by systemic deposition of light chains in various organs, with the 
kidneys being most commonly affected. There have been few reports of isolated LCDD. We 
report a rare case of LCDD limited to a duodenal polyp. A 63-yr-old man visited our 
hospital for health screening without symptoms in 2009. On gastrofiberscopy, a duodenal 
polyp was observed. The biopsy showed diffuse infiltration by atypical plasma cells, which 
were positive for kappa-type light chains by immunohistochemistry. While the patient 
refused further management, we could find no evidence of recurrence until 2 yr after the 
initial diagnosis. It has been reported that isolated LCDD has relatively good prognosis 
compared to systemic LCDD. However, treatment for this disease has not been established 
yet. 
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Light chain deposition disease (LCDD) is a systemic disease 
characterized by clonal proliferation of plasma cells, overpro-
duction of abnormal light chains, and deposition of non-amy-
loid monoclonal immunoglobulin light chains in various organs, 
which can induce organ dysfunction, especially in the kidney 
(1, 2). This disorder was originally described by Randall et al. (5) 
in 1976 in two patients with end-stage renal disease (ESRD) 
with granular deposition of free light chains that did not stain 
with Congo red on kidney pathologic evaluation. There have 
only been a few reports of isolated LCDD involving the brain 
(3), lungs (4), cervical lymph nodes (5), and pharynx (6). Here, 
we report one case of LCDD limited to the duodenal mucosa. 
Based on laboratory and radiologic tests, especially normal se-
rum and urine-free light chain levels, we conclude that no sys-
temic signs of the disease were present in this patient at any 
time point in the disease process. 
CASE DESCRIPTION
A 63-yr-old man visited Chung-Ang University Hospital for a 
regular examination without any symptoms or complaints on 
March 1st, 2009. An esophagogastroduodenoscopy revealed a 
polypoid mass in the duodenal bulb measuring approximately 
2 cm (Fig. 1). An endoscopic biopsy from the mass showed a 
deposition of pink, amorphous material and infiltration of plas-
ma cells in the lamina propria (Fig. 2A). Congo red staining was 
negative (Fig. 2B). A few plasma cells showed λ light chain (LC) 
immunohistochemical staining (Fig. 2C), although most plas-
ma cells were κ light chain-positive (Fig. 2D).
  Following the biopsy results, a complete skeletal X-ray survey, 
abdomino-pelvic computed tomography (CT), bone marrow 
histology (including karyotyping and serum/urine-free LC lev-
els), serum/urine immunofixation electrophoresis, and serum/
urine protein electrophoresis were performed. No abdominal 
mass was palpated on physical examination. The CT scan 
showed multiple inhomogeneous polypoid masses in the duo-
denum (Fig. 3). Lymphadenopathy was not detected. A serum-
free LC assay revealed slight elevation of kappa chains at 28.4 
mg/L (normal range, 3.3-19.4 mg/L), while lambda chains were 
normal at 25.2 mg/L (normal range, 5.71-26.3 mg/L) with a 
normal λ:k ratio of 1.13 (normal range, 0.26-1.65). A mild pre-
dominance of serum kappa chains was consistent with the kap-
pa stained-positive duodenal polyp. Serum beta-2-microglob-
ulin was elevated at 2.43 mg/L (normal range, 0.81-2.19 mg/L). 
A subsequent work-up (serum/urine protein electrophoresis, 
radiographic examination of the axial skeleton, and a bone mar-
row aspirate and biopsy) was completely negative. A bone mar-
row aspirate and biopsy revealed 1.2% plasma cells and normal Kim H-J, et al.  •  Isolated Light Chain Deposition Disease
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cytogenetics. Laboratory testing was normal, as follows: white 
blood cell count, 5,880/μL; hemoglobin, 15.4 g/dL; platelet, 
212,000/μL; blood urea nitrogen, 13 mg/dL; creatinine, 1.1 mg/
dL; total protein, 6.7 g/dL; albumin, 3.7 g/dL; and 24-hr-urine 
protein, 1.6 g/dL. On the basis of these features, localized LCDD 
in the duodenum was diagnosed. The patient refused aggressive 
treatment or regular follow-up. Thereafter, any polyps around 
the duodenum were not observed in arbitrarily applicated 
esophagogastroduodenoscopy on May 5th, 2011.
Fig. 1. Esophagogastroduodenoscopy showing polypoid mass in the duodenal bulb. Fig. 3. Abdominal CT showing multiple polypoid mass in the duodenum. There are 
multiple inhomogeneous polypoid masses in the duodenum (arrowheads).
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Fig. 2. Histopathology of duodenal mucosa. (A) Deposition of pale pink amorphous materials and infiltration of plasma cells in the lamina propria (H&E stain, × 400). (B) Nega-
tive reaction on Congo red staining (× 400). (C) Positive reaction in plasma cells with anti-κ light chain antibodies (IHC stain, × 400). (D) Negative reaction with anti-λ light 
chain antibodies (IHC stain, × 400).Kim H-J, et al.  •  Isolated Light Chain Deposition Disease
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DISCUSSION
LCDD is a rare clinicopathologic entity characterized by tissue 
deposition of non-amyloid immunoglobulin light chains (7). 
LCDD affects middle-aged patients ranging from 35-76 yr, with 
a mean of 56 yr. LCDD affects men 2.5 times more often than 
women (1). LCDD is usually associated with monoclonal gam-
mopathies of undetermined significance in 17% of patients and 
MM in 58% of patients (8). However, there were no reports of 
LCDD involving a duodenal polyp. Unlike AL amyloidosis, one 
of the monoclonal light chain deposition diseases in tissues, 
LCDD does not stain with Congo red, which displays green bi-
refringence under polarization. 
  Clinical manifestations of LCDD are related to the underly-
ing condition and the location of deposits. Renal involvement is 
consistently present and is characterized by proteinuria and 
microscopic hematuria. In most patients with LCDD, renal 
function declines rapidly as a rapidly progressive glomerulone-
phritis (1) or as an acute tubulointerstital nephritis (9), which is 
due to progressive accumulation of light chains from plasma 
filtration and includes proteinuria, nephrotic syndrome, and/
or renal failure. Symptomatic extrarenal deposition is rare and 
has been described in the heart (10, 11), liver (12), lungs (1, 9, 
10), joints (11), and central and peripheral nervous systems (3). 
It is uncertain whether or not localized LCDD really exists or 
represents an initial expression of a silent systemic LCDD (5).
  Among nonamyloid monoclonal immunoglobulin deposi-
tion disorders, the most frequent form of is κ light chain deposi-
tion disease (13, 14), which was also the diagnosis of this case. 
Lamda light chain deposition represents 15%-20%, and com-
bined light and heavy chain deposition fewer than 10% of the 
reported cases. As the clinical presentation in LCDD is known 
to depend on the number and nature of the organs affected, 
deposition of different light chains does not seem to affect their 
clinical course.
  The median duration of survival in systemic LCDD is approxi-
mately 4 yr. Prognostic factors for LCDD include age, presence 
of plasma cell myeloma, and extrarenal light chain deposition 
(9). The treatment of LCDD has not been established. Chemo-
therapy with steroids and melphalan has been used, but the re-
sponse rates have been low (15). A combination of high-dose 
melphalan and autologous stem cell transplantation has been 
reported to improve renal function in affected patients (16), but 
high mortality rates and side effects limit this regimen (17).
  In conclusion, we have reported the first case of LCDD in-
volving the duodenum alone in an asymptomatic patient. A 
less aggressive clinical course was expected in the patient pre-
sented herein compared to patients with systemic involvement 
of LCDD, but long-term follow-up is necessary to establish the 
clinical significance of isolated LCDD.
REFERENCES
1. Pozzi C, D’Amico M, Fogazzi GB, Curioni S, Ferrario F, Pasquali S, Quat-
trocchio G, Rollino C, Segagni S, Locatelli F. Light chain deposition dis-
ease with renal involvement: clinical characteristics and prognostic fac-
tors. Am J Kidney Dis 2003; 42: 1154-63.
2. Buxbaum JN, Chuba JV, Hellman GC, Solomon A, Gallo GR. Monoclo-
nal immunoglobulin deposition disease: light chain and light and heavy 
chain deposition diseases and their relation to light chain amyloidosis. 
Clinical features, immunopathology, and molecular analysis. Ann Intern 
Med 1990; 112: 455-64.
3. Popovic M, Tavcar R, Glavac D, Volavsek M, Pirtosek Z, Vizjak A. Light 
chain deposition disease restricted to the brain: the first case report. Hum 
Pathol 2007; 38: 179-84.
4. Piard F, Yaziji N, Jarry O, Assem M, Martin L, Bernard A, Jacquot JP, Jus-
trabo E. Solitary plasmacytoma of the lung with light chain extracellular 
deposits: a case report and review of the literature. Histopathology 1998; 
32: 356-61.
5. Rostagno A, Frizzera G, Ylagan L, Kumar A, Ghiso J, Gallo G. Tumoral 
non-amyloidotic monoclonal immunoglobulin light chain deposits (‘ag-
gregoma’): presenting feature of B-cell dyscrasia in three cases with im-
munohistochemical and biochemical analyses. Br J Haematol 2002; 119: 
62-9.
6. Zidar N, Zver S, Jurcic V. Extraosseus plasmacytoma of the pharynx with 
localized light chain deposition. Case report. Pathol Oncol Res 2010; 16: 
249-52.
7. Buxbaum J, Gallo G. Nonamyloidotic monoclonal immunoglobulin de-
position disease. Light-chain, heavy-chain, and light- and heavy-chain 
deposition diseases. Hematol Oncol Clin North Am 1999; 13: 1235-48.
8. Lin J, Markowitz GS, Valeri AM, Kambham N, Sherman WH, Appel GB, 
D’Agati VD. Renal monoclonal immunoglobulin deposition disease: the 
disease spectrum. J Am Soc Nephrol 2001; 12: 1482-92.
9. McKenna RW, Kyle RA, Kuehl WM, Grogan TM, Harris NL, Coupland 
RW. Plasma cell neoplasms in WHO classification of tumours of haema-
topoietic and lymphoid tissues: International Agency for Research on 
Cancer, Lyon; 2008.
10. Khoor A, Myers JL, Tazelaar HD, Kurtin PJ. Amyloid-like pulmonary 
nodules, including localized light-chain deposition: clinicopathologic 
analysis of three cases. Am J Clin Pathol 2004; 121: 200-4.
11. Rivest C, Turgeon PP, Senecal JL. Lambda light chain deposition disease 
presenting as an amyloid-like arthropathy. J Rheumatol 1993; 20: 880-4.
12. Pozzi C, Locatelli F. Kidney and liver involvement in monoclonal light 
chain disorders. Semin Nephrol 2002; 22: 319-30.
13. Faa G, Van Eyken P, De Vos R, Fevery J, Van Damme B, De Groote J, 
Desmet VJ. Light chain deposition disease of the liver associated with 
AL-type amyloidosis and severe cholestasis. A case report and literature 
review. J Hepatol 1991; 12: 75-82.
14. Buxbaum JN, Chuba JV, Hellmann GC, Solomon A, Gallo GR. Mono-
clonal immunoglobulin deposition disease: light chain and light and 
heavy chain deposition disease and their relation to light chain amyloi-
dosis. Ann Intern Med 1990; 112: 455-64.
15. Heilman RL, Velosa JA, Holley KE, Offord KP, Kyle RA. Long-term fol-
low-up and response to chemotherapy in patients with light-chain depo-
sition disease. Am J Kidney Dis 1992; 20: 34-41.
16. Royer B, Arnulf B, Martinez F, Roy L, Flageul B, Etienne I, Ronco P, Kim H-J, et al.  •  Isolated Light Chain Deposition Disease
210   http://jkms.org http://dx.doi.org/10.3346/jkms.2012.27.2.207
Brouet JC, Fermand JP. High dose chemotherapy in light chain or light 
and heavy chain deposition disease. Kidney Int 2004; 65: 642-8.
17. Lorenz EC, Gertz MA, Fervenza FC, Dispenzieri A, Lacy MQ, Hayman 
SR, Gastineau DA, Leung N. Long-term outcome of autologous stem cell 
transplantation in light chain deposition disease. Nephrol Dial Trans-
plant 2008; 23: 2052-7.